1969–70 1. Slovenská národná hokejová liga season

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

Retrieved on: 
Tuesday, May 9, 2023

As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.

Key Points: 
  • As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.
  • “Today’s announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company,” said David Moatazedi, Evolus’ President and Chief Executive Officer.
  • “We are excited to expand our portfolio with Evolysse™, a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau®.
  • “We are particularly excited to partner with Evolus in bringing our next-generation HA filler product line to the U.S.

Global Blue Releases the Monthly Tax Free Shopping Business Update for January 2023

Retrieved on: 
Thursday, February 9, 2023

New data from Global Blue (NYSE:GB) shows that the dynamic recovery for Tax Free Shopping has continued to strengthen across Continental Europe and Asia Pacific.

Key Points: 
  • New data from Global Blue (NYSE:GB) shows that the dynamic recovery for Tax Free Shopping has continued to strengthen across Continental Europe and Asia Pacific.
  • In Asia Pacific, the dynamic recovery continues to propel, reaching 96%1 in January vs. the same period in 2019.
  • Japan remains a leader in the region with a strong and steady recovery.
  • In Continental Europe, recovery is stabilized at 106%1 in January 2023 vs. the same period in 2019.

NYC REIT Sends Letter Urging Shareholders to Vote for Company’s Incumbent Director Nominee as Annual Meeting Approaches

Retrieved on: 
Friday, May 20, 2022

NYC strongly encourages all shareholders to vote on the GOLD proxy card FOR the reelection of Elizabeth Tuppeny and protect their investment.

Key Points: 
  • NYC strongly encourages all shareholders to vote on the GOLD proxy card FOR the reelection of Elizabeth Tuppeny and protect their investment.
  • Further, NYC advises shareholders discard the white proxy card that they may receive from Comrit.
  • NYC has paid an attractive $0.40 per share annual dividend, even during the harsh times of the Covid-19 pandemic.
  • The total value that has been created under Ms. Tuppenys as lead independent director of the Board is truly exceptional.

NYC REIT Comments on Institutional Shareholder Services Report

Retrieved on: 
Wednesday, May 18, 2022

New York City REIT, Inc. (NYSE: NYC) (NYC or the Company) today issued the following statement in response to the report issued by Institutional Shareholder Services (ISS) relating to the director election at the Companys Annual Meeting on May 31, 2022.

Key Points: 
  • New York City REIT, Inc. (NYSE: NYC) (NYC or the Company) today issued the following statement in response to the report issued by Institutional Shareholder Services (ISS) relating to the director election at the Companys Annual Meeting on May 31, 2022.
  • Michael Weil, Chairman and CEO of NYC, said, There is no question that Elizabeth Tuppeny is the superior candidate and the right choice for NYC shareholders in the upcoming director election.
  • She has been an outstanding NYC director for several years and has extensive commercial real estate experience, significant REIT board service, and a strong track record of delivering exceptional returns to our shareholders.
  • About New York City REIT, Inc.
    New York City REIT, Inc. is a publicly traded REIT that owns a portfolio of high-quality commercial real estate located within the five boroughs of New York City.

Evolus Reports First Quarter 2022 Results and Provides Business Update

Retrieved on: 
Tuesday, May 10, 2022

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Momentum in the companys business continues to build with its lead metrics reaching all-time highs this quarter.
  • Evolus added 575 new customer accounts in the first quarter, the highest quarterly increase in the past two years.
  • This program provides Evolus with the opportunity to offer the first multi-strength neurotoxin, giving customers and consumers increased treatment options.